Pharmacological treatment of chronic obstructive pulmonary disease: From evidence-based medicine to phenotyping

Drug Discovery Today

Volumn 19, Issue 12, 2014, Pages 1928-1935

  Montuschi, Paolo ^a   Malerba, Mario ^b   Santini, Giuseppe ^b   Miravitlles, Marc ^c  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABEDITEROL; ACLIDINIUM BROMIDE; ACLIDINIUM BROMIDE PLUS FORMOTEROL FUMARATE; ANTIINFECTIVE AGENT; ARFORMOTEROL; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CARMOTEROL; CORTICOSTEROID; FLUTICASONE FUROATE PLUS VILANTEROL; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; LEVALBUTEROL; MILVETEROL; OLODATEROL; OLODATEROL PLUS TIOTROPIUM BROMIDE; ROFLUMILAST; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; UNINDEXED DRUG; VILANTEROL;

ACOS OVERLAP SYNDROME; AIRWAY OBSTRUCTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; CHRONIC BRONCHITIS; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; EMPHYSEMA; ENDOPLASMIC RETICULUM; EOSINOPHIL COUNT; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; NONHUMAN; PERSONALIZED MEDICINE; PHENOTYPE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFLAMMATION; SMOOTH MUSCLE FIBER; TREATMENT RESPONSE; ANIMAL; CLASSIFICATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ANIMALS; ASTHMA; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84916203277     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.08.004     Document Type: Review

References (60)

1. Anonymous American Thoracic Society Statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 152 1995 S77 S120
2. R.A. Pauwels Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 163 2001 1256 1276
3. R.D. Yusen Evolution of the GOLD documents for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Controversies and questions Am. J. Respir. Crit. Care Med. 188 2013 4 5
4. 4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD Respir. Res. 12 2011 e18
5. R.K. Albert Azithromycin for prevention of exacerbations of COPD N. Engl. J Med. 365 2011 689 698
6. M. Miravitlles Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity Arch. Bronconeumol. 47 2011 271-271
7. D. Anderson, and W. MacNee Targeted treatment in COPD: a multi-system approach for a multi-system disease Int. J. Chron. Obst. Pulm. Dis. 4 2009 321 335
8. M.K. Han Chronic obstructive pulmonary disease phenotypes: the future of COPD Am. J. Respir. Crit. Care Med. 182 2010 598 604
9. J.B. Soriano The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom Chest 124 2003 474 481
10. B. Burrows The emphysematous and bronchial types of chronic airflow obstruction Lancet 1 1966 830 835
11. P. Montuschi Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD Curr. Med. Chem. 20 2013 1464 1476
12. L. Fuso Long-acting beta-agonists and their association with inhaled corticosteroids in COPD Curr. Med. Chem. 20 2013 1477 1495
13. E. Kerwin Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Eur. Respir. J. 40 2012 1106 1114
14. A.F. Gelb Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD Respir. Med. 107 2013 1957 1965
15. J. Beier Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study COPD 10 2013 511 522
16. 3 muscarinic receptors in the contraction of rat and human small airways Eur. J. Pharmacol. 702 2013 109 115
17. E.D. Bateman Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study Eur. Respir. J. 42 2013 1484 1494
18. C.F. Vogelmeier Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study Lancet Respir. Med. 1 2013 51 60
19. J.E. Frampton QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease Drugs 74 2014 465 488
20. L.J. Scott, and P. Hair Umeclidinium/vilanterol: first global approval Drugs 74 2014 389 395
21. G.J. Feldman, and A. Edin The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects Ther. Adv. Respir. Dis. 7 2013 311 319
22. E.D. Bateman Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD Pulm. Pharmacol. Ther. 26 2013 581 587
23. J.R. Hurst Susceptibility to exacerbation in chronic obstructive pulmonary disease N. Engl. J. Med. 363 2010 1128 1138
24. J.J. Soler Cataluña The frequent exacerbator. A new phenotype in COPD? Hot Topics Respir. Med. 6 2011 7 12
25. J.K. Quint Predictive accuracy of patient-reported exacerbation frequency in COPD Eur. Respir. J. 37 2011 501 507
26. J.J. Soler-Cataluña Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Thorax 60 2005 925 931
27. M. Miravitlles Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD Arch. Bronconeumol. 48 2012 247 257
28. M. Montes de Oca Chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study Eur. Respir. J. 40 2012 28 36
29. V. Kim The chronic bronchitic phenotype of COPD. An analysis of the COPD Gene study Chest 140 2011 626 633
30. S. Sethi Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial Respir. Res. 11 2010 e10
31. P.J. Poole, and P.N. Black Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease Cochrane Database Syst. Rev. 3 2006 eCD001287
32. J.P. Zheng Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebo-controlled study Lancet 371 2008 2013 2018
33. M. Decramer Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial Lancet 365 2005 1552 1560
34. M.K. Han Chronic obstructive pulmonary disease exacerbations in the COPD Gene Study: associated radiologic phenotypes Radiology 261 2011 274 282
35. M. Bafadhel Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers Am. J. Respir. Crit. Care Med. 184 2011 662 671
36. J. Hurst Exacerbation phenotyping in chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 184 2011 625 626
37. M. Bafadhel Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease. A randomized placebo-controlled trial Am. J. Respir. Crit. Care Med. 186 2012 48 55
38. T. Suzuki Erythromycin and common cold in COPD Chest 120 2001 730 733
39. T.A. Seemungal Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations Am. J. Respir. Crit. Care Med. 178 2008 1139 1147
40. X. Pomares Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations Int. J. Chron. Obstruct. Pulmon. Dis. 6 2011 449 456
41. F. Blasi Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy Pulmon. Phamacol. Ther. 23 2010 200 207
42. Z-Y. He Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease Respiration 80 2010 445 452
43. D.J. Serisier Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases Lancet Respir. Med. 1 2013 262 274
44. R. De Marco Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm Am. J. Respir. Crit. Care Med. 175 2007 32 39
45. P.G. Gibson, and J.L. Simpson The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 64 2009 728 735
46. M. Miravitlles The overlap syndrome between asthma and COPD: implications for management Hot Topics Respir. Med. 16 2011 15 20
47. M. Hardin The clinical features of the overlap between COPD and asthma Respir. Res. 12 2011 e127
48. J.J. Soler Cataluña Consensus document on the overlap phenotype COPD-asthma in COPD Arch. Bronconeumol. 48 2012 331 337
49. M. Miravitlles Difficulties in differential diagnosis of COPD and asthma in primary care Br. J. Gen. Pract. 62 2012 e68 e75
50. D.E. O'Donnell Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update Can. Respir. J. 14 Suppl. B 2007 5B 32B
51. A. Nagai Guidelines for the Diagnosis and Treatment of COPD edn 3 2009 The Japanese Respiratory Society
52. C.E. Brightling Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease Thorax 60 2005 193 198
53. R. Leigh Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Eur. Respir. J. 27 2006 964 971
54. C.E. Brightling Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial Lancet 356 2000 1480 1485
55. P. White Overtreatment of COPD with inhaled corticosteroids: implications for safety and costs: cross-sectional observational study PLoS ONE 8 2013 e75221
56. R. Siva Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial Eur. Respir. J. 29 2007 906 913
57. H. Magnussen Improvements with tiotropium in COPD patients with concomitant asthma Respir. Med. 102 2008 50 56
58. P.M.A. Calverley Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N. Engl. J. Med. 356 2007 775 778
59. A. Gibb, and L.P. Yang Olodaterol: first global approval Drugs 73 2013 1841 1846
60. M. Miravitlles Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice Eur. Respir. J. 41 2013 1252 1256